Effect of selenium as an adjunctive therapy in patients with treatment-resistant obsessive-compulsive disorder: A pilot randomized double blind placebo-controlled clinical trial
More details
Hide details
jundishpour University
Submission date: 2018-07-03
Final revision date: 2018-11-03
Acceptance date: 2018-11-05
Publication date: 2018-12-12
Corresponding author
mehdi Sayyah   

jundishpour University, golestan Ave, 123456 Ahvaz, Iran
Arch Psych Psych 2018;20(4):57-65
Aim of the study:
The first line medicinal treatment of Obsessive Compulsive Disorder includes Selective Serotonin Reuptake Inhibitors (SSRIs).Researchers have shown that there is a correlation between the trace elements deficiency such as selenium and mental disorders and mood, since selenium is a safe and non-tolerable side-effect supplementation that may be useful as an adjunctive treatment with SSRIs.

Subject or material and methods:
Thirty-two patients with a treatment-resistant obsessive-compulsive disorder were selected and randomly entered into two groups: intervention and control, while both groups continued to consume SSRI drugs according to the current procedure. The intervention group received one 200 mcg selenium capsule daily and each daily control group received one capsule of placebo for 6 weeks.

Y-BOCS scores decreased at the end of the sixth week in both groups, but this reduction was significantly lower in the selenium group (P = 0.01). Selenium was well tolerated and there was no significant difference between the two groups in the incidence of side effects

The results of this study indicate that selenium as an adjunctive treatment with SSRIs improves symptoms

Selenium can be as new drug for treatment of Refractory OCD.

Journals System - logo
Scroll to top